UBS Group AG Grows Holdings in DENTSPLY SIRONA Inc. $XRAY

UBS Group AG grew its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 63.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,701,980 shares of the medical instruments supplier’s stock after purchasing an additional 662,000 shares during the period. UBS Group AG’s holdings in DENTSPLY SIRONA were worth $19,454,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of XRAY. Mitsubishi UFJ Trust & Banking Corp increased its stake in DENTSPLY SIRONA by 1,836.7% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 105,938 shares of the medical instruments supplier’s stock valued at $1,344,000 after purchasing an additional 100,468 shares during the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of DENTSPLY SIRONA by 38.4% during the 3rd quarter. Commonwealth Equity Services LLC now owns 804,934 shares of the medical instruments supplier’s stock worth $10,215,000 after acquiring an additional 223,339 shares during the period. Invenomic Capital Management LP boosted its position in shares of DENTSPLY SIRONA by 48.7% in the third quarter. Invenomic Capital Management LP now owns 4,351,199 shares of the medical instruments supplier’s stock worth $55,217,000 after acquiring an additional 1,425,637 shares during the last quarter. Sound Income Strategies LLC grew its holdings in DENTSPLY SIRONA by 32.3% in the fourth quarter. Sound Income Strategies LLC now owns 611,308 shares of the medical instruments supplier’s stock valued at $7,464,000 after purchasing an additional 149,384 shares during the period. Finally, Skba Capital Management LLC increased its position in DENTSPLY SIRONA by 14.3% during the third quarter. Skba Capital Management LLC now owns 1,140,430 shares of the medical instruments supplier’s stock worth $14,472,000 after purchasing an additional 142,900 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

Insider Activity

In related news, Director James D. Forbes acquired 5,000 shares of DENTSPLY SIRONA stock in a transaction on Monday, March 9th. The shares were bought at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at $124,800. This trade represents a 100.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gregory T. Lucier bought 27,555 shares of the stock in a transaction dated Monday, March 2nd. The stock was bought at an average price of $14.24 per share, with a total value of $392,383.20. Following the purchase, the director owned 27,555 shares of the company’s stock, valued at approximately $392,383.20. This represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 70,000 shares of company stock worth $956,437 over the last three months. 0.52% of the stock is currently owned by corporate insiders.

DENTSPLY SIRONA Trading Down 0.8%

Shares of XRAY stock opened at $10.91 on Tuesday. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of -3.46, a price-to-earnings-growth ratio of 1.31 and a beta of 0.93. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $17.18. The firm’s 50 day moving average price is $11.99 and its two-hundred day moving average price is $11.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). The business had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.DENTSPLY SIRONA’s revenue was up .1% on a year-over-year basis. During the same period in the previous year, the company earned $0.43 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current year.

Analysts Set New Price Targets

XRAY has been the topic of a number of recent analyst reports. Barrington Research increased their price target on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Zacks Research raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their target price for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Wells Fargo & Company lifted their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Finally, UBS Group lowered their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday. Three investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $13.82.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.